Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNMT1 | P26358 | 5/20 | 0.47 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.47 |
| ▸ | TK1 | P04183 | 4/20 | 0.43 |
| ▸ | ALB | P02768 | 2/20 | 0.43 |
| ▸ | DNMT3B | Q9UBC3 | 1/20 | 0.42 |
| ▸ | TK2 | O00142 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL445989 | 1.00 | DNMT1 (0.47) | DNMT1ADRB1TK1ALBDNMT3B | |
| SCHEMBL20466819 | 0.87 | DNMT1 (0.63) | DNMT1ADRB1TK1DNMT3BTK2 | |
| SCHEMBL442302 | 0.87 | DNMT1 (0.48) | DNMT1ADRB1TK1ALBDNMT3B | |
| SCHEMBL14450224 | 0.87 | DNMT1 (0.63) | DNMT1ADRB1TK1DNMT3BTK2 | |
| SCHEMBL844010 | 0.87 | DNMT1 (0.63) | DNMT1ADRB1TK1DNMT3BTK2 | |
| SCHEMBL20268 | 0.87 | DNMT1 (0.63) | DNMT1ADRB1TK1DNMT3BTK2 | |
| SCHEMBL442301 | 0.87 | DNMT1 (0.48) | DNMT1ADRB1TK1ALBDNMT3B | |
| SCHEMBL5953088 | 0.87 | DNMT1 (0.63) | DNMT1ADRB1TK1DNMT3BTK2 | |
| SCHEMBL5983910 | 0.87 | DNMT1 (0.63) | DNMT1ADRB1TK1DNMT3BTK2 | |
| SCHEMBL30616797 | 0.87 | DNMT1 (0.63) | DNMT1ADRB1TK1DNMT3BTK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060106065-A1 | Methods of treating hepatitis virus infections with N-substituted-1,5-dideoxy-1,5-imino-D- glucuitol compounds in combination therapy | JACOB GARY S | 2006-05-18 | — | — | US | claimed |
| US-20050119310-A1 | Use of n-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds for treating hepatitis virus infections | PHARMACIA CORPORATION | 2005-06-02 | — | — | US | claimed |
| US-6689759-B1 | COMBINED WITH NUCLEOSIDE AND/OR NUCLEOTIDE ANTIVIRAL AGENTS AND IMMUNOSTIMULANTS | G. D. SEARLE & CO. | 2004-02-10 | — | — | US | claimed |
| US-20030220299-A1 | Especially treating hepatitis B and hepatitis C; may be used alone, or in combination with another antiviral agent such as nucleosides, nucleotides, immunomodulators, and/or immunostimulants | G.D. SEARLE & CO. | 2003-11-27 | — | — | US | claimed |
| US-20030195229-A1 | Glucamine salts for treating hepatitis virus infections | PHARMACIA CORPORATION | 2003-10-16 | — | — | US | claimed |
| US-20030100532-A1 | USE OF N-SUBSTITUTED-1,5-DIDEOXY-1,5-IMINO-D-GLUCITOL COMPOUNDS IN COMBINATION THERAPY FOR TREATING HEPATITIS VIRUS INFECTIONS | UNITED THERAPEUTICS CORPORATION | 2003-05-29 | — | — | US | claimed |
| EP-1261339-A1 | USE OF N-SUBSTITUTED-1,5-DIDEOXY-1,5-IMINO-D-GLUCITOL COMPOUNDS FOR TREATING HEPATITIS VIRUS INFECTIONS | Pharmacia Corporation (US) | 2002-12-04 | — | — | EP | claimed |
| JP-2002502875-A | — | — | 2002-01-29 | — | — | JP | claimed |
| WO-2001060366-A1 | USE OF N-SUBSTITUTED-1,5-DIDEOXY-1,5-IMINO-D-GLUCITOL COMPOUNDS FOR TREATING HEPATITIS VIRUS INFECTIONS | PHARMACIA CORPORATION (US) | 2001-08-23 | — | — | WO | claimed |
| EP-1061922-A1 | USE OF $i(N)-SUBSTITUTED-1,5-DIDEOXY-1,5-IMINO-D-GLUCITOL COMPOUNDS FOR TREATING HEPATITIS VIRUS INFECTIONS | G.D. SEARLE & CO. (US) | 2000-12-27 | — | — | EP | claimed |
| WO-1999040916-A1 | USE OF N-SUBSTITUTED-1,5-DIDEOXY-1,5-IMINO-D-GLUCITOL COMPOUNDS FOR TREATING HEPATITIS VIRUS INFECTIONS | G.D. SEARLE & CO. (US) | 1999-08-19 | — | — | WO | claimed |
| US-20140294763-A1 | PEPTIDOMIMETIC PROTEASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2014-10-02 | — | — | US | disclosed |
| EP-2368877-B1 | Peptidomimetic protease inhibitors and intermediates for their preparation As treatment for HCV infection | VERTEX PHARMA (US) | 2014-05-07 | — | — | EP | disclosed |
| US-20130344476-A1 | HEPATITIS C VIRUS VARIANTS | VERTEX PHARMACEUTICALS INCORPORATED | 2013-12-26 | — | — | US | disclosed |
| EP-1958956-B1 | Peptidomimetic protease inhibitors | VERTEX PHARMA (US) | 2013-12-11 | — | — | EP | disclosed |
| WO-2002018369-A2 | PEPTIDOMIMETIC PROTEASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2002-03-07 | — | — | WO | disclosed |
| WO-2001060366-A1 | USE OF N-SUBSTITUTED-1,5-DIDEOXY-1,5-IMINO-D-GLUCITOL COMPOUNDS FOR TREATING HEPATITIS VIRUS INFECTIONS | PHARMACIA CORPORATION (US) | 2001-08-23 | — | — | WO | disclosed |
| EP-1061922-A1 | USE OF $i(N)-SUBSTITUTED-1,5-DIDEOXY-1,5-IMINO-D-GLUCITOL COMPOUNDS FOR TREATING HEPATITIS VIRUS INFECTIONS | G.D. SEARLE & CO. (US) | 2000-12-27 | — | — | EP | disclosed |
| WO-1999040916-A1 | USE OF N-SUBSTITUTED-1,5-DIDEOXY-1,5-IMINO-D-GLUCITOL COMPOUNDS FOR TREATING HEPATITIS VIRUS INFECTIONS | G.D. SEARLE & CO. (US) | 1999-08-19 | — | — | WO | disclosed |
| EP-0409227-A2 | Pyrimidine nucleosides, their preparation and pharmaceutical preparations | MATTHES, Eckart, Dr. (DE) | 1991-01-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030195229-A1 | Glucamine salts for treating hepatitis virus infections | UGGT1, GYS2, MGAT3 | DNMT1 2645/4885ADRB1 456/4885TK1 235/4885 |
| US-20030100532-A1 | USE OF N-SUBSTITUTED-1,5-DIDEOXY-1,5-IMINO-D-GLUCITOL COMPOUNDS IN COMBINATION THERAPY FOR TREATING HEPATITIS VIRUS INFECTIONS | HAVCR2, DERA, GALE | DNMT1 1313/4885ADRB1 2389/4885TK1 263/4885 |
| US-20140294763-A1 | PEPTIDOMIMETIC PROTEASE INHIBITORS | CTSC, PREP, PEPD | DNMT1 4819/4885ADRB1 4015/4885TK1 1121/4885 |
| US-20050119310-A1 | Use of n-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds for treating hepatitis virus infections | HAVCR2, DERA, IMPDH1 | DNMT1 1522/4885ADRB1 1944/4885TK1 310/4885 |
| US-20060106065-A1 | Methods of treating hepatitis virus infections with N-substituted-1,5-dideoxy-1,5-imino-D- glucuitol compounds in combination therapy | HAVCR2, DERA, UGGT1 | DNMT1 2042/4885ADRB1 2292/4885TK1 299/4885 |
| US-20030220299-A1 | Especially treating hepatitis B and hepatitis C; may be used alone, or in combination with another antiviral agent such as nucleosides, nucleotides, immunomodulators, and/or immunostimulants | IMPDH1, HAVCR2, IMPDH2 | DNMT1 1899/4885ADRB1 994/4885TK1 250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.